Objective:

To assess 5-year national trends and sociodemographic disparities in the prevalence of coexisting CHD-COPD co-morbidity.

Approach:

• Data Source: Used the 2020−2024 National Health Interview Survey Integrated Public Use Microdata Series adults' dataset to estimate national prevalence.
• Statistical Analysis: Employed weighted descriptive statistics, multivariate regression models, and sensitivity analysis to examine associations.

Key Findings:

• CHD-COPD co-morbidity prevalence remained stable at approximately 0.35%–0.43% annually from 2020 to 2024.
• No statistically significant increase in prevalence was observed (OR per 1-year increase = 1.04; 95% CI: 0.997–1.08; p = 0.072).
• Older age, smoking status, and sociodemographic factors were strong independent predictors of CHD-COPD co-morbidity.

Interpretation:

Smoking, older age, male sex, lower income, and Southern residence were identified as significant predictors of CHD-COPD co-morbidity.

Limitations:

• The study may not capture all relevant sociodemographic factors influencing co-morbidity.
• The cross-sectional nature of the data limits causal inferences.

Conclusion:

CHD-COPD co-morbidity is clinically significant, with a stable adjusted prevalence of approximately 0.35%–0.43% annually among United States adults from 2020 to 2024.